Research programme: p38 MAP kinase inhibitors - Amphora

Drug Profile

Research programme: p38 MAP kinase inhibitors - Amphora

Latest Information Update: 18 Apr 2007

Price : $50

At a glance

  • Originator Amphora Discovery Corporation
  • Class
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 17 Jan 2005 Amphora Discovery Corporation and Ortho-McNeil Pharmaceutical have entered into a research collaboration regarding anti-inflammatory drugs
  • 26 Aug 2004 Preclinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top